TABLE 4.
Evolution of the combination based on the indication
| Indication a | All | Patients with active IBD | Patients with both active IBD and active IMID/EIM | Patient with active IMID/EIM | |
|---|---|---|---|---|---|
| Group A | Group B | Group C | |||
| N = 104 a | N = 70 | N = 10 | N = 23 | ||
| Total combo duration: 1467.5 months/104 combinations | |||||
| Percentage of patients with ongoing/stopped combination at last visit (n, %) | |||||
| Ongoing | 57 (55) | 41 (59) | 6 (60) | 10 (43) | |
| Stopped | 47 (45) | 29 (41) | 4 (40) | 13 (57) | |
| Percentage of patients on combination at 6 and 12 months among patients with documented follow‐up (n, %) | |||||
| >6 months | 69/91 (76) | 45/60 (75) | 8/9 (89) | 15/21 (71) | |
| >12 months | 36/62 (58) | 24/41 (59) | 4/7 (57) | 8/14 (57) | |
Abbreviations: EIM, extra‐intestinal manifestation; IBD, Inflammatory bowel disease; IMID, immune mediated inflammatory disease.
a
One combination Risankizumab + Tacrolimus for IBD and liver transplantation.